19 May 2022 US FDA accepts Cytovation's IND application for Phase II combination studies of CyPep-1, a first-in-class targeted tumor membrane immunotherapy
19 May 2022 EMA accepts filing of marketing authorization application for Valneva’s inactivated COVID-19 Vaccine Candidate
18 May 2022 Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
17 May 2022 Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an 'Off-The-Shelf' Cancer Immunotherapy Developed using Nouscom's Proprietary Viral Vector Platform
13 May 2022 Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster
10 May 2022 Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
02 May 2022 VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
02 May 2022 HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants
20 Apr 2022 Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
20 Apr 2022 Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
20 Apr 2022 Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults
18 Apr 2022 Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
11 Apr 2022 Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022
30 Mar 2022 TolerogenixX Receives Approval to Start Phase IIb Trial for its Immune Tolerance-Inducing MIC-Lx Cell Therapy
30 Mar 2022 HDT Bio Doses First Healthy Volunteer in US Phase 1 Trial of Next Generation COVID-19 Variant RNA Vaccine
30 Mar 2022 Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
29 Mar 2022 Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
29 Mar 2022 CyanVac and Blue Lake Biotechnology Announce FDA Clearance of IND Application for BLB-201 Intranasal RSV Vaccine
19 Mar 2022 Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
19 Mar 2022 Moderna's Omicron-specific bivalent booster candidate (mRNA-1273.214) combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)
19 Mar 2022 Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
16 Mar 2022 Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
09 Mar 2022 BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC
08 Mar 2022 Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
05 Mar 2022 Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up